Glypican-1 Antibody / GPC1

Glypican-1, also known as GPC1, is a glycosylphosphatidylinositol (GPI) -anchored cell surface proteoglycan that plays a crucial role in various cellular processes, including cell growth, differentiation, and signaling pathways. Recent studies have shown that GPC1 is overexpressed in many types of cancer, including pancreatic, breast, and prostate cancer. This overexpression is thought to contribute to the aggressiveness and metastatic potential of these tumors, making GPC1 a potential target for cancer therapy. One of the key functions of GPC1 in cancer is its ability to interact with growth factors and signaling molecules, such as Wnt and Hedgehog, to promote tumor growth and progression. By blocking the interaction between GPC1 and these molecules, researchers believe they can inhibit the growth of cancer cells and potentially prevent metastasis. In addition to its role in promoting cancer progression, GPC1 has also been found to be a promising biomarker for early detection and prognosis of cancer. Researchers have developed novel diagnostic tools that detect circulating GPC1 levels in the blood, allowing for earlier detection of cancer and more accurate monitoring of treatment response.